Trial Profile
Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 16 Feb 2021
Price :
$35
*
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Heart failure
- Focus Expanded access; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 10 Feb 2021 Status changed from recruiting to completed.
- 27 Oct 2016 Status changed from completed to recruiting.
- 01 Oct 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.